Qiagen, DiaSorin debut Lyme disease assay

By LabPulse.com staff writers

April 21, 2021 -- Qiagen and DiaSorin announced the launch of the Liaison LymeDetect assay for early detection of the Lyme Borreliosis infection. The test detects immunoglobulin G (IgG) and immunoglobulin M (IgM) antibodies and cellular immunity.

The test has a sensitivity of 74% and a specificity of 100% within 21 days from the first evidence of infection. It is available in markets accepting the CE Mark, and those that use the Liaison analyzer systems.

Qiagen is responsible for product development and manufacturing, and DiaSorin is handling its global commercialization.

Qiagen secures EUA for COVID-19 test
Qiagen has received emergency use authorization (EUA) from the U.S. Food and Drug Administration for NeuMoDx, a test that helps clinicians distinguish...
Qiagen launches automated sample processing for molecular testing
Qiagen has announced the launch of a fully automated sample processing platform for IVD applications in molecular diagnostic laboratories.
Qiagen, Inovio to partner on cervical dysplasia test
Qiagen and Inovio have announced they will develop a next-generation sequencing test for HPV-linked advanced cervical dysplasia that can be used on Illumina's...
Qiagen plans FDA resubmission of coronavirus rapid antigen test
Qiagen is planning a first-quarter resubmission of its QIAreach rapid antigen test to the U.S. Food and Drug Administration (FDA). In separate news, the...
Qiagen debuts solution for SARS-CoV-2 T-cell research
Qiagen has launched the QuantiFeron SARS-CoV-2 Research Use Only solution to detect T-cell responses to the novel coronavirus. The solution could aid...

Copyright © 2021 LabPulse.com

Last Updated ls 4/21/2021 4:11:44 PM



Subscribe Today
Do you want to be a Microbiology Insider?

When LabPulse gets hot new information, our Insiders are the first to find out. Stay current in today's competitive market by receiving our exclusive free email updates.

Yes, Keep Me Current